← Leaderboards
Natarajan Muthusamy
Ohio State University
$5,466,792
Attributed
$8,818,845
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,818,845 · 7
By mechanism
R01$5,967,729 · 4
P01$2,424,848 · 2
R21$426,268 · 1
Top collaborators
- John C Byrd5 shared
- Guido Marcucci5 shared
- Mitch A Phelps5 shared
- Kenneth K Chan3 shared
- Christoph Rader2 shared
- Ben Shen1 shared
Most similar at Ohio State University
Same institution · by research overlap
- Dehua Pei$17,575,721
- Mitch A Phelps$6,387,631
- Dalia Elgamal$886,253
- N. Stanley Nahman Jr$591,429
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelIn VivoDesignMediatingTreatment EfficacyPre-ClinicalAntibodiesXenograft ProcedureGenerationsTransgenic OrganismsSuccessChronic Lymphocytic LeukemiaNatural Killer CellsAnimalsImmuneSignal TransductionMaintenanceProgramsGene TargetingLeukemiaMalignant NeoplasmsCellsBiologicalNatural Immunity
Grant awards (28)
Novel Enediyne-Based Antibody-Drug Conjugates for Cancers$685,157
R01 · FY2025 · CA
Phosphatase activation as therapeutic strategy for Chronic lymphocyic leukemia$424,526
R01 · FY2019 · CA · contact PI
Validation of Siglec-6 as a novel target for cancer immunotherapy$179,804
R21 · FY2019 · CA
Phosphatase activation as therapeutic strategy for Chronic lymphocyic leukemia$437,656
R01 · FY2018 · CA · contact PI
Validation of Siglec-6 as a novel target for cancer immunotherapy$246,464
R21 · FY2018 · CA
Phosphatase activation as therapeutic strategy for Chronic lymphocyic leukemia$437,656
R01 · FY2017 · CA · contact PI
Phosphatase activation as therapeutic strategy for Chronic lymphocyic leukemia$437,656
R01 · FY2016 · CA · contact PI
Novel Immunotherapies for Lymphoid Malignancies$316,438
R01 · FY2016 · CA
MOUSE MODELING AND ANIMAL DEVELOPMENT$247,366
P01 · FY2016 · CA · contact PI
Phosphatase activation as therapeutic strategy for Chronic lymphocyic leukemia$437,656
R01 · FY2015 · CA · contact PI
Novel Immunotherapies for Lymphoid Malignancies$316,438
R01 · FY2015 · CA
Validation of microRNAs as therapeutic targets in hematological malignancies$316,438
R01 · FY2015 · CA · contact PI
MOUSE MODELING AND ANIMAL DEVELOPMENT$247,366
P01 · FY2015 · CA · contact PI
Validation of microRNAs as therapeutic targets in hematological malignancies$306,945
R01 · FY2014 · CA · contact PI
Novel Immunotherapies for Lymphoid Malignancies$306,945
R01 · FY2014 · CA
MOUSE MODELING AND ANIMAL DEVELOPMENT$239,944
P01 · FY2014 · CA · contact PI
Novel Immunotherapies for Lymphoid Malignancies$297,452
R01 · FY2013 · CA
Validation of microRNAs as therapeutic targets in hematological malignancies$297,452
R01 · FY2013 · CA
MOUSE MODELING AND ANIMAL DEVELOPMENT$232,885
P01 · FY2013 · CA · contact PI
Validation of microRNAs as therapeutic targets in hematological malignancies$316,438
R01 · FY2012 · CA
Novel Immunotherapies for Lymphoid Malignancies$316,438
R01 · FY2012 · CA
MOUSE MODELING AND ANIMAL DEVELOPMENT$248,855
P01 · FY2012 · CA · contact PI
Validation of microRNAs as therapeutic targets in hematological malignancies$316,438
R01 · FY2011 · CA
MOUSE MODELING AND ANIMAL DEVELOPMENT$245,001
P01 · FY2011 · CA · contact PI
MOUSE MODELING AND ANIMAL DEVELOPMENT$252,597
P01 · FY2010 · CA · contact PI
MOUSE MODELING AND ANIMAL DEVELOPMENT$247,666
P01 · FY2009 · CA · contact PI
MOUSE MODELING AND ANIMAL DEVELOPMENT$239,562
P01 · FY2008 · CA · contact PI
MOUSE MODELING AND ANIMAL DEVELOPMENT$223,606
P01 · FY2007 · CA · contact PI